HealthRx.com

Stephen A. Smith and GLP-1: The Documented Public Record

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Stephen A. Smith and GLP-1: The Documented Public Record
Clinical image for Stephen A. Smith and GLP-1: The Documented Public Record Image: HealthRX.com clinical image

What Stephen A. Smith Has Said Publicly

Stephen A. Smith, the longtime ESPN commentator and host of First Take, has publicly acknowledged using GLP-1 medication. During on-air segments, Smith discussed his experience with the drug class and the effect it had on his health and physical appearance. His willingness to address the topic in a broadcast setting, rather than through a carefully managed PR statement, gave the disclosure a candid quality that resonated with viewers.

Smith's public commentary focused on the results he experienced: reduced appetite, weight loss, and what he described as an overall improvement in how he felt. He did not shy away from the subject when co-hosts or guests raised it, and at times brought it up himself.

The specific GLP-1 compound Smith used has not been confirmed through public statements with brand-name precision. The two most widely prescribed GLP-1 receptor agonists in the U.S. are semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) and tirzepatide (marketed as Mounjaro and Zepbound). Without a direct brand-name confirmation from Smith, this page addresses the GLP-1 class broadly.

How GLP-1 Receptor Agonists Work

GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in the gut after eating. It does three things that matter for weight and metabolic health: it signals the pancreas to release insulin in a glucose-dependent manner, it slows gastric emptying, and it acts on appetite centers in the hypothalamus to reduce hunger.

Synthetic GLP-1 receptor agonists mimic this hormone but with a much longer half-life. Semaglutide, for example, has a half-life of approximately one week, which is why it's dosed as a once-weekly injection. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin pathways simultaneously. Clinical trials have shown tirzepatide produces greater mean weight loss than semaglutide alone, though head-to-head data continues to evolve.

For someone like Smith, a man in his late 50s with a high-profile, high-stress career, the clinical rationale for GLP-1 therapy extends beyond aesthetics. Excess adiposity in middle-aged men is associated with increased risk of cardiovascular events, insulin resistance, obstructive sleep apnea, and joint degeneration. The SELECT trial, published in The New England Journal of Medicine, demonstrated that semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, independent of diabetes status.

Dose Escalation and What the First Months Typically Look Like

GLP-1 medications follow a dose-escalation protocol. Semaglutide starts at 0.25 mg weekly for four weeks, then increases to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg for weight management (per the FDA-approved Wegovy label). Tirzepatide starts at 2.5 mg and can be titrated up to 15 mg weekly.

This slow ramp matters. Most side effects, primarily gastrointestinal (nausea, constipation, diarrhea), occur during the early escalation phase and tend to diminish as the body adjusts. In the STEP 1 trial, approximately 44% of participants on semaglutide reported nausea at some point during treatment, but discontinuation due to GI events was under 5%.

Weight loss typically becomes visible within 8 to 12 weeks and continues for 12 to 18 months before plateauing. In STEP 1, mean weight loss at 68 weeks was 14.9% of body weight with semaglutide versus 2.4% with placebo.

The HealthRX.com Medical Team Take

From the HealthRX.com Medical Team's perspective, Smith's case illustrates several points worth examining.

First, his demographic profile. Men over 50 are statistically underrepresented in GLP-1 prescription data relative to their cardiovascular risk burden. Women account for the majority of semaglutide and tirzepatide prescriptions, partly because of cultural factors around weight management and partly because of marketing patterns. A high-profile man in Smith's age bracket openly discussing GLP-1 use may shift that calculus for men who would benefit from the medication but view it as something "not for them."

Second, the performance dimension. Smith's job requires sustained cognitive sharpness, vocal endurance, and on-camera energy across multi-hour broadcast windows. Weight loss through caloric restriction alone can produce fatigue, irritability, and reduced cognitive performance, particularly in the early weeks. GLP-1 medications reduce caloric intake through appetite suppression rather than willpower-dependent restriction, which data suggest preserves cognitive function and daily energy expenditure more effectively than behavioral dieting alone.

Third, the muscle-mass question. One persistent concern with GLP-1 therapy is lean mass loss. The STEP 1 trial found that roughly 40% of total weight lost was lean mass, a ratio consistent with any weight-loss intervention. For a man in his late 50s, preserving muscle is critical for metabolic rate, joint stability, and long-term functional capacity. The HealthRX.com Medical Team recommends concurrent resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) for any patient on GLP-1 therapy, consistent with 2023 guidance from the Endocrine Society.

What Happens When You Stop

A question Smith has not publicly addressed is long-term duration of use. The STEP 1 extension data showed that participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of lost weight within one year. This is not unique to GLP-1 drugs. It reflects the biology of obesity: the hypothalamus defends a higher body-weight set point through increased hunger signaling and decreased energy expenditure after weight loss.

Current clinical consensus, reflected in the American Gastroenterological Association's 2024 guidelines, treats GLP-1 medications as long-term or indefinite therapy for most patients, similar to statins for cholesterol or antihypertensives for blood pressure. The framing of obesity as a chronic disease requiring sustained pharmacotherapy is still relatively new in public consciousness, and celebrity disclosures like Smith's contribute to normalizing that framing.

Why This Public Disclosure Matters

Smith occupies a specific media niche. His audience skews male, sports-focused, and spans a wide age range. Many of his viewers are men in their 40s, 50s, and 60s, a group with high rates of obesity-related comorbidity and low rates of proactive medical engagement. When Smith discusses GLP-1 use on camera, it reaches a population that pharmaceutical marketing and physician outreach often miss.

The HealthRX.com Medical Team views this as a net positive for public health literacy, with one caveat: GLP-1 medications require medical supervision, dose titration, and monitoring for complications including pancreatitis, gallbladder disease, and (in patients with personal or family history of medullary thyroid carcinoma) thyroid C-cell tumor risk. The FDA maintains a boxed warning on semaglutide products related to thyroid C-cell tumors observed in rodent studies. Celebrity endorsement, even when honest and well-intentioned, cannot substitute for individualized clinical evaluation.

At a glance

  • Status: Stephen A. Smith has publicly confirmed using GLP-1 medication, discussed on ESPN's First Take
  • Drug class: GLP-1 receptor agonists (specific compound not publicly confirmed by brand name)
  • Documented outcomes: Weight loss and reduced appetite, per Smith's own on-air statements
  • Key clinical context: GLP-1 drugs reduce appetite via hypothalamic signaling and slow gastric emptying; typical weight loss is 10-15% of body weight over 12-18 months
  • HealthRX.com Medical Team note: Smith's audience demographics (men 40-60+) represent a population that is undertreated relative to cardiovascular risk, making his disclosure particularly relevant to public health

Frequently asked questions

›
›
›
›
›

References

For More Info Visit HealthRx.com
Visit Now